ELDN Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

IRVINE, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a panel presentation at the upcoming Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023, at 8:00 a.m. ET.

To register in advance for the panel presentation webcast, sign up .

A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at .

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals is a clinical stage biotechnology company with immunology expertise that is developing therapies to protect and prevent rejection of transplanted organs, as well as to treat amyotrophic lateral sclerosis (ALS). The Company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, California. For more information, please visit the company’s website at .

Follow Eledon Pharmaceuticals on social media: ; 

Investor Contact:

Stephen Jasper

Gilmartin Group

(858) 525 2047

Media Contact:

Jenna Urban

Berry & Company Public Relations

(212) 253 8881

Source: Eledon Pharmaceuticals



EN
20/09/2023

Underlying

ELDNEledon Pharmaceuticals Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eledon Pharmaceuticals Inc

 PRESS RELEASE
Free
ELDN Eledon Pharmace...

Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlo...

Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 IRVINE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steven Perrin, Ph.D., President and Chief Scientific Officer will participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 10:00 a.m. ET (7:00 a.m. PT). To register in advance for the fireside chat webcast, sign up . A webcast replay will be accessible following the live session on the Company’s we...

February 5, 2026 1 EN
 PRESS RELEASE
Free
ELDN Eledon Pharmace...

Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubar...

Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium Data from eight participants continue to support safety and tolerability profile of tegoprubart Mean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months IRVINE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will present 24-month follow-up data from eight patients enrolled in the Phase ...

January 23, 2026 1 EN
 PRESS RELEASE
Free
ELDN Eledon Pharmace...

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provi...

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase 3 development Reported positive preliminary results from first six patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Tegoprubart continues to be used as key component of immunosuppression regimen in xenotransplants, including three transplants of a genetically modified pig kidne...

January 8, 2026 1 EN
 PRESS RELEASE
Free
ELDN Eledon Pharmace...

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler...

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference IRVINE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer will participate in a fireside chat at the upcoming 37th Annual Piper Sandler Healthcare Conference on Thursday, December 4, 2025 at 8:50 a.m. ET (5:50 a.m. PT). To register in advance for the fireside chat webcast, sign up . A webcast replay will be accessible following the live session on the Company’s website under...

December 1, 2025 1 EN
 PRESS RELEASE
Free
ELDN Eledon Pharmace...

Eledon Reports Preliminary Data from First Six Patients with Type 1 Di...

Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine IRVINE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced preliminary results from an investigator-initiated trial conducted at the University of Chicago Medicine’s Transplant Institute and presented at the Rachmiel Levine-Arthur Riggs Diabetes Research Symposium, held November 14-17, 2025 at City of Hope in Los A...

November 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch